{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T03:30:44Z","timestamp":1768966244450,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.japh.2025.102906","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T01:01:45Z","timestamp":1755651705000},"page":"102906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of budesonide\/glycopyrrolate\/formoterol fumarate compared with glycopyrrolate\/formoterol fumarate for the treatment of COPD: A systematic review and meta-analysis"],"prefix":"10.1016","author":[{"given":"Piyush","family":"Thathera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakriti","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2075-5550","authenticated-orcid":false,"given":"Shaista","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd Ashif","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.japh.2025.102906_bib1","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1007\/s12325-020-01311-3","volume":"37","author":"Ferguson","year":"2020","journal-title":"Adv. Ther"},{"key":"10.1016\/j.japh.2025.102906_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211034329","article-title":"Improvements in lung function with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial","volume":"15","author":"Rabe","year":"2021","journal-title":"Ther Adv Respir Dis"},{"issue":"3","key":"10.1016\/j.japh.2025.102906_bib3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2332\/allergolint.11-OA-0411","article-title":"Glucocorticoids inhibit MUC5AC production induced by transforming growth factor-in human respiratory cells","volume":"61","author":"Takami","year":"2012","journal-title":"Allergol Int"},{"issue":"12","key":"10.1016\/j.japh.2025.102906_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46598","article-title":"Global burden of chronic obstructive pulmonary disease through 2050","volume":"6","author":"Boers","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.japh.2025.102906_bib6","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.2147\/COPD.S220861","article-title":"Long-term safety and efficacy of budesonide\/ glycopyrrolate\/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology in Japanese patients with COPD","volume":"14","author":"Ichinose","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"10.1016\/j.japh.2025.102906_bib7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1513\/pats.200504-026SR","article-title":"Systemic effects of chronic obstructive pulmonary disease","volume":"2","author":"Agust\u00ed","year":"2005","journal-title":"Proc Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.japh.2025.102906_bib8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1183\/09031936.06.00143704","article-title":"The potential impact of anaemia of chronic disease in COPD","volume":"27","author":"Similowski","year":"2006","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.japh.2025.102906_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00063198-199903000-00003","article-title":"Worldwide epidemiology of chronic obstructive pulmonary disease","volume":"5","author":"Chen","year":"1999","journal-title":"Curr Opin Pulm Med"},{"issue":"9064","key":"10.1016\/j.japh.2025.102906_bib10","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(96)07492-2","article-title":"Alternative projections of mortality and disability by cause 1990\u20132020: global Burden of Disease Study","volume":"349","author":"Murray","year":"1997","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.japh.2025.102906_bib11","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1513\/AnnalsATS.202001-023OC","article-title":"Triple Therapy versus dual or monotherapy with Long-Acting bronchodilators for chronic obstructive pulmonary disease. A systematic review and meta-analysis","volume":"17","author":"Mammen","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.japh.2025.102906_bib12","article-title":"Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis","volume":"363","author":"Zheng","year":"2018","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.japh.2025.102906_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Med"},{"issue":"3","key":"10.1016\/j.japh.2025.102906_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/1574886313666180601082412","article-title":"Risk and benefit profile of dulaglutide in established therapeutic indication","volume":"13","author":"Garg","year":"2018","journal-title":"Curr Drug Saf"},{"issue":"4","key":"10.1016\/j.japh.2025.102906_bib15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2174\/0115748855292051240327084430","article-title":"Effects of orexin receptor antagonist on cognitive function in adults: a systematic review","volume":"20","author":"Jha","year":"2025","journal-title":"Curr Drug Ther"},{"issue":"1","key":"10.1016\/j.japh.2025.102906_bib16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12931-021-01772-2","article-title":"Functional respiratory imaging assessment of budesonide\/glycopyrrolate\/formoterol fumarate and glycopyrrolate\/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids","volume":"22","author":"van den Berge","year":"2021","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.japh.2025.102906_bib17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease a randomized, double-blind, multicenter, parallel-group study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"suppl 14","key":"10.1016\/j.japh.2025.102906_bib18","doi-asserted-by":"crossref","first-page":"S1800","DOI":"10.21037\/jtd.2019.06.12","article-title":"Update on management of stable chronic obstructive pulmonary disease","volume":"11","author":"Agrawal","year":"2019","journal-title":"J Thorac Dis"},{"issue":"2 suppl","key":"10.1016\/j.japh.2025.102906_bib19","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1378\/chest.117.2_suppl.1S","article-title":"The impact of COPD on lung health worldwide: epidemiology and incidence","volume":"117","author":"Hurd","year":"2000","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.japh.2025.102906_bib20","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1183\/09031936.03.00031403","article-title":"What do chronic obstructive pulmonary disease patients die from? Amultiple cause coding analysis","volume":"22","author":"Hansell","year":"2003","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.japh.2025.102906_bib21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3109\/15412555.2010.481697","article-title":"The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review","volume":"7","author":"Toy","year":"2010","journal-title":"COPD"},{"issue":"5 suppl","key":"10.1016\/j.japh.2025.102906_bib22","doi-asserted-by":"crossref","first-page":"121S","DOI":"10.1378\/chest.121.5_suppl.121S","article-title":"COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity","volume":"121","author":"Mannino","year":"2002","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.japh.2025.102906_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jand.2019.12.001","article-title":"Chronic obstructive pulmonary disease: a 2019 evidence analysis center evidence-based practice guideline","volume":"121","author":"Hanson","year":"2021","journal-title":"J Acad Nutr Diet"},{"issue":"2","key":"10.1016\/j.japh.2025.102906_bib24","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.05.020415","article-title":"Global and regional estimates of COPD prevalence: systematic review and meta\u2013analysis","volume":"5","author":"Adeloye","year":"2015","journal-title":"J Glob Health"},{"key":"10.1016\/j.japh.2025.102906_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069679","article-title":"Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990\u20132019: results from the Global Burden of Disease Study 2019","volume":"378","author":"Safiri","year":"2022","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.japh.2025.102906_bib26","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1164\/rccm.200703-456SO","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"176","author":"Anthonisen","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.japh.2025.102906_bib27","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3949\/ccjm.74.12.869","article-title":"Primary care diagnosis of alpha-1 antitrypsin deficiency: issues and opportunities","volume":"74","author":"Stoller","year":"2007","journal-title":"Cleve Clin J Med"},{"issue":"1","key":"10.1016\/j.japh.2025.102906_bib28","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2147\/COPD.S21917","article-title":"Functional imaging using computer methods to compare the effect of salbutamol and ipratropium bromide in patient-specific airway models of COPD","volume":"6","author":"De Backer","year":"2011","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"18","key":"10.1016\/j.japh.2025.102906_bib29","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"issue":"10048","key":"10.1016\/j.japh.2025.102906_bib30","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(16)30828-5","article-title":"Super-spreading events of MERS-CoV infection","volume":"388","author":"Hui","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.japh.2025.102906_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(19)30248-6","article-title":"Small airways dysfunction: is there any involvement in patients with atopy? \u2013 authors\u2019 reply","volume":"7","author":"Kraft","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.japh.2025.102906_bib32","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3389\/fphar.2019.00390","article-title":"Single inhaler LABA\/LAMA for COPD","volume":"10","author":"Malerba","year":"2019","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.japh.2025.102906_bib33","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01805-2016","article-title":"The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease","volume":"50","author":"Burgstaller","year":"2017","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.japh.2025.102906_bib34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1164\/ajrccm.164.6.2007062","article-title":"Lung tissue mechanics and extracellular matrix remodeling in acute lung injury","volume":"164","author":"Rocco","year":"2001","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319125005850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319125005850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:56:43Z","timestamp":1768921003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319125005850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":33,"alternative-id":["S1544319125005850"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2025.102906","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of budesonide\/glycopyrrolate\/formoterol fumarate compared with glycopyrrolate\/formoterol fumarate for the treatment of COPD: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2025.102906","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102906"}}